BioPharma Today

Regarding BioPharma Today

Josh — Fri, 01 Mar 2013 06:25:23 PST

As of March 1, 2013, we will no longer be updating the BioPharma Today web site and email. We recommend the following free resources to stay up to date with Biopharmaceutical news and analysis from Elsevier Business Intelligence: Get free...

Coming in Friday's "The Pink Sheet" DAILY

Wendy Diller — Thu, 28 Feb 2013 10:48:22 PST

Takeda Pharmaceuticals has inked an option agreement with Resolve Therapeutics for a pre-clinical lupus drug.

Latest News From "The Pink Sheet" DAILY - Antibiotic Play Optimer Looks At Options

Wendy Diller — Thu, 28 Feb 2013 07:18:11 PST

Securities Fraud Class Action Suits Could Grow After Amgen Supreme Court Loss

Coming In Thursday's "The Pink Sheet" DAILY - Optimer Explores Its Options

Wendy Diller — Wed, 27 Feb 2013 10:24:28 PST

The antibiotic company Optimer announced it is reviewing strategic options and that CEO Petdro Lichtinger has been replaced by Chairman Henry McKinnell. Multiple anti-infective rivals looking to beef up their portfolios with a commercial asset could drive a competitive process.

Latest News From "The Pink Sheet" DAILY - Aveo's Tivozanib Faces ODAC May 2

Wendy Diller — Wed, 27 Feb 2013 06:35:36 PST

Aveo's Tivozanib Will Face Challenging Survival Data At ODAC Review FDA's Oncologic Drugs Advisory Committee will consider the tyrosine kinase inhibitor for advanced renal cell carcinoma at a May 2 meeting. Aveo has attributed a negative overall survival trend in the TIVO-1 study to a crossover design and use of post-progression therapies among patients randomized to the comparator arm.

Latest News From "The Pink Sheet" DAILY - Royalty Pharma Makes A Play For Elan

Wendy Diller — Tue, 26 Feb 2013 07:19:32 PST

For Elan Investors, A Choice Between A Sure Thing Or A High-Risk Play

Coming In Tuesday's "The Pink Sheet" DAILY - Royalty Pharma Makes A Move For Elan

Wendy Diller — Mon, 25 Feb 2013 10:24:37 PST

Royalty Pharma’s $11 per-share bid for Elan is too low, according to Elan’s management and industry analysts.

Save the Date!

Josh — Mon, 25 Feb 2013 09:40:20 PST

The 2nd PharmAsia-Shanghai Summit will take place October 21-23, 2013. Join us and our partners BayHelix as we feature real life data and case studies, networking opportunities, and strategic reports from emerging markets in Asia. For more information on Sponsorship...

Scientific Advances Increase Potential For Drugs To Treat ALS

Josh — Mon, 25 Feb 2013 07:41:51 PST

New understanding of the spectrum of CNS disorders and rising interest from biotechs have revealed new targets, new biomarkers and new opportunities to treat the fast-acting and deadly neurodegenerative disease. Add to that an open stakeholder forum hosted by FDA Feb. 25 that could clarify regulatory and clinical expectations, and the tide may be turning on amyotrophic lateral sclerosis.

Latest News From "The Pink Sheet" DAILY - Roche's Kadcyla Clears FDA

Wendy Diller — Mon, 25 Feb 2013 06:46:20 PST

Kadcyla Positioned For Wide Use In Metastatic Breast Cancer

Coming In Monday's "The Pink Sheet" DAILY - EMA Panel Again Rejects Vivus' Obesity Drug Qsiva

Wendy Diller — Fri, 22 Feb 2013 10:14:01 PST

European Medicines Agency committee recommends Vivus' Qsiva not be approved - Financings of the Fortnight looks at pending IPOs - Kolltan Pharmaceuticals prepares to move to new stage - Compounding pharmacy association says its position on non-traditional manufacturing is consistent

Latest News From "The Pink Sheet" DAILY - GPhA Objects To Amgen Push To Restrict Biosimilar Substitution

Wendy Diller — Fri, 22 Feb 2013 09:58:57 PST

GPhA president calls out Amgen for supporting biosimilar substitution restrictions - Flu vaccines unlikely to get preferential recommendations from ACIP - Germany's IQWiG rejects BMS/AZ's Komboglyze for type 2 diabetes - Israel's Immune Pharmaceuticals to merge with EpiCept - France's Rhenovia Pharma to boost biosimulation use in CNS R&D